• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Integrated analysis of circulating tumour cells and circulating tumour DNA to detect minimal residual disease in hepatocellular carcinoma.

作者信息

Zhao Lina, Jiang Liping, Liu Yunhe, Wang Xuebing, Song Jinge, Sun Yulin, Bai Yinlei, Dong Xiu, Sun Liying, Wu Jianxiong, Jiao Yuchen, Zhao Xiaohang

机构信息

State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Clin Transl Med. 2022 Apr;12(4):e793. doi: 10.1002/ctm2.793.

DOI:10.1002/ctm2.793
PMID:35384341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8982315/
Abstract
摘要

相似文献

1
Integrated analysis of circulating tumour cells and circulating tumour DNA to detect minimal residual disease in hepatocellular carcinoma.循环肿瘤细胞与循环肿瘤DNA的综合分析以检测肝细胞癌中的微小残留病
Clin Transl Med. 2022 Apr;12(4):e793. doi: 10.1002/ctm2.793.
2
Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma.循环游离肿瘤DNA与肝细胞癌疾病表型分析的前景
Oncogene. 2018 Aug;37(34):4635-4638. doi: 10.1038/s41388-018-0262-8. Epub 2018 May 14.
3
Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma.探索循环肿瘤DNA的超低通量全基因组测序在肝细胞癌中的预后价值。
Clin Mol Hepatol. 2024 Apr;30(2):160-163. doi: 10.3350/cmh.2024.0141. Epub 2024 Feb 28.
4
Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma.循环肿瘤 DNA/循环肿瘤细胞及其在不同病因诱导的肝细胞癌中的适用性。
Curr Probl Cancer. 2020 Apr;44(2):100516. doi: 10.1016/j.currproblcancer.2019.100516. Epub 2019 Nov 18.
5
Circulating tumour DNA for detection of minimal residual disease in head and neck squamous cell carcinoma: A new hope.循环肿瘤DNA用于检测头颈部鳞状细胞癌的微小残留病：新希望
Ann Oncol. 2023 Dec;34(12):1080-1081. doi: 10.1016/j.annonc.2023.10.693.
6
Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.循环肿瘤 DNA 在肝细胞癌精准医学中的前景与挑战。
Clin Exp Med. 2020 Aug;20(3):329-337. doi: 10.1007/s10238-020-00620-9. Epub 2020 Apr 1.
7
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.循环肿瘤 DNA 甲基化标志物用于肝细胞癌的诊断和预后。
Nat Mater. 2017 Nov;16(11):1155-1161. doi: 10.1038/nmat4997. Epub 2017 Oct 9.
8
Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.肝细胞癌长期随访患者循环肿瘤 DNA 和蛋白质生物标志物的综合液体分析。
Clin Cancer Res. 2019 Sep 1;25(17):5284-5294. doi: 10.1158/1078-0432.CCR-18-3477. Epub 2019 Jun 19.
9
Current and future perspectives of liquid biopsies in genomics-driven oncology.液体活检在基于基因组学的肿瘤学中的现状与未来展望。
Nat Rev Genet. 2019 Feb;20(2):71-88. doi: 10.1038/s41576-018-0071-5.
10
The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies.循环肿瘤 DNA 在评估腔道胃肠恶性肿瘤微小残留病中的作用。
Clin Adv Hematol Oncol. 2022 Jul;20(7):444-455.

引用本文的文献

1
Updates on Liquid Biopsy and ctDNA in Transplant Oncology.移植肿瘤学中液体活检与循环肿瘤DNA的最新进展
Cancers (Basel). 2025 Jun 10;17(12):1930. doi: 10.3390/cancers17121930.
2
Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer.门静脉循环肿瘤细胞作为切除胰腺癌复发预测的生物标志物。
Cell Mol Life Sci. 2025 Apr 10;82(1):155. doi: 10.1007/s00018-025-05669-x.
3
Liquid biopsies in cancer.癌症中的液体活检

本文引用的文献

1
Plasma-only ctDNA-Guided MRD Detection in Patients with CRC-Response.仅血浆循环肿瘤DNA指导的结直肠癌患者微小残留病检测——反应情况
Clin Cancer Res. 2021 Dec 1;27(23):6614-6615. doi: 10.1158/1078-0432.CCR-21-3306.
2
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
3
Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma.
Mol Biomed. 2025 Mar 20;6(1):18. doi: 10.1186/s43556-025-00257-8.
4
Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.日本临床肿瘤学会关于分子残留病（MRD）检测合理临床应用的立场文件。
Int J Clin Oncol. 2025 Apr;30(4):605-654. doi: 10.1007/s10147-024-02683-0. Epub 2025 Feb 7.
5
Minimal residual disease as a target for liquid biopsy in patients with solid tumours.微小残留病作为实体瘤患者液体活检的靶点。
Nat Rev Clin Oncol. 2025 Jan;22(1):65-77. doi: 10.1038/s41571-024-00967-y. Epub 2024 Nov 28.
6
Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications.肝细胞癌中的液体活检：挑战、进展及临床意义
Clin Mol Hepatol. 2025 Feb;31(Suppl):S255-S284. doi: 10.3350/cmh.2024.0541. Epub 2024 Nov 28.
7
3D genomic mapping reveals multifocality of human pancreatic precancers.3D 基因组图谱揭示人类胰腺前癌的多灶性。
Nature. 2024 May;629(8012):679-687. doi: 10.1038/s41586-024-07359-3. Epub 2024 May 1.
8
Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.基于循环肿瘤 DNA 的可切除癌症分子残留病检测：系统评价和荟萃分析。
EBioMedicine. 2024 May;103:105109. doi: 10.1016/j.ebiom.2024.105109. Epub 2024 Apr 13.
9
Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives.肝切除术后及热消融后肝细胞癌复发的管理：现状与未来展望
Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):71-88. doi: 10.21037/hbsn-22-579. Epub 2023 Jun 19.
10
Minimal residual disease in solid tumors: an overview.实体瘤中的微小残留病：概述
Front Med. 2023 Aug;17(4):649-674. doi: 10.1007/s11684-023-1018-6. Epub 2023 Sep 14.
子宫内膜癌癌前病变的全基因组突变分析。
J Pathol. 2021 Jan;253(1):119-128. doi: 10.1002/path.5566. Epub 2020 Nov 13.
4
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.新辅助化疗后循环肿瘤 DNA 和循环肿瘤细胞与三阴性乳腺癌患者疾病复发的关系：BRE12-158 随机临床试验的预先计划的二次分析。
JAMA Oncol. 2020 Sep 1;6(9):1410-1415. doi: 10.1001/jamaoncol.2020.2295.
5
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.循环肿瘤 DNA 分析作为 III 期结肠癌辅助治疗复发风险和获益的标志物。
JAMA Oncol. 2019 Dec 1;5(12):1710-1717. doi: 10.1001/jamaoncol.2019.3616.
6
Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.肝细胞癌长期随访患者循环肿瘤 DNA 和蛋白质生物标志物的综合液体分析。
Clin Cancer Res. 2019 Sep 1;25(17):5284-5294. doi: 10.1158/1078-0432.CCR-18-3477. Epub 2019 Jun 19.
7
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.I至III期结直肠癌患者血浆游离DNA的深度测序分析
JAMA Oncol. 2019 Aug 1;5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528.
8
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.采用超深度血浆游离 DNA 测序对膀胱癌患者进行转移性复发的早期检测和治疗效果监测。
J Clin Oncol. 2019 Jun 20;37(18):1547-1557. doi: 10.1200/JCO.18.02052. Epub 2019 May 6.
9
Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy.液体活检在无症状 HBsAg 阳性个体中早期检测肝细胞癌。
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6308-6312. doi: 10.1073/pnas.1819799116. Epub 2019 Mar 11.
10
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.循环肿瘤细胞、疾病进展与转移性乳腺癌患者的生存情况
N Engl J Med. 2004 Aug 19;351(8):781-91. doi: 10.1056/NEJMoa040766.